## **Product** Data Sheet

## **CCND2 Protein, Human (His)**

Cat. No.: HY-P7773

Synonyms: rHuCCND2, His; G1/S-specific cyclin-D2; CCND2

Species: Human Source: E. coli

Accession: P30279 (M1-L289)

Gene ID: 894

Molecular Weight: Approximately 35 kDa

## **PROPERTIES**

	_		
$\Lambda \Lambda$	500	uen	60
ᄶ	Jeu	uen	CC

HHHHHMELL CHEVDPVRRA VRDRNLLRDD RVLQNLLTIE ERYLPQCSYF KCVQKDIQPY MRRMVATWML EVCEEQKCEE EVFPLAMNYL DRFLAGVPTP KSHLQLLGAV CMFLASKLKE TSPLTAEKLC IYTDNSIKPQ  $\mathsf{E}\;\mathsf{L}\;\mathsf{L}\;\mathsf{E}\;\mathsf{W}\;\mathsf{E}\;\mathsf{L}\;\mathsf{V}\;\mathsf{V}\;\mathsf{L}$ GKLKWNLAAV TPHDFIEHIL RKLPQQREKL SLIRKHAQTF IALCATDFKF AMYPPSMIAT GSVGAAICGL QQDEEVSSLT CDALTELLAK ITNTDVDCLK ACQEQIEAVL LNSLQQYRQD QRDGSKSEDE

RDIDL LDQASTPTDV

**Appearance** 

Solution.

Formulation

Supplied as a 0.2 μm filter solution of 20 mM Tris,150 mM NaCl, 5 mM DTT, pH 7.5.

**Endotoxin Level** 

<1 EU/µg, determined by LAL method.

Reconsititution

N/A

Storage & Stability

Stored at -80°C for 1 year. It is stable at -20°C for 3 months after opening. It is recommended to freeze aliquots at -80°C for extended storage. Avoid repeated freeze-thaw cycles.

**Shipping** 

Shipping with dry ice.

## **DESCRIPTION**

Background

CCND2 (Cyclin D2), is a member of the Cyclin family, along with Cyclin D1, Cyclin D3, and Cyclin E, which act as cell cycle regulatory proteins. CCND2 promotes cell cycle progression by binding and activating cyclin-dependent kinase 4 (cdk4)/cdk6. The activated CCND2-cdk4/cdk6 complex over-phosphorylates the tumor suppressor protein pRB, promotes the release, and activation of the transcription factor E2F, and targets the production of several proteins required to regulate cell cycle progression. CCND2 is abnormally expressed in a variety of malignant tumors, including colorectal,

	prostate, and bladder cancers. The function of CCND2 is primarily related to the regulation of cell cycle <sup>[1]</sup> .	
DEFEDENCES		
REFERENCES		
[1]. Di Wang, et al. CCND2 mRN.	NA Expression Is Correlated With R-CHOP Treatment Efficacy and Prognosis in Patients With ABC-DLBCL. Front Oncol. 2020 Jul 21;10::	1180.
	Continue Broad and have a fall would have a financial continue from the continue for the co	
	Caution: Product has not been fully validated for medical applications. For research use only.	
	Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com  Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA	

Page 2 of 2 www.MedChemExpress.com